<DOC>
	<DOCNO>NCT01348555</DOCNO>
	<brief_summary>Pulmonary administer anticholinergic agent show importance chronic obstructive pulmonary disease ( COPD ) management reduce morbidity , disability mortality . To date , recommend treatment moderate severe COPD patient consist combination ß2 agonist long act antimuscarinic compound . There still medical need new product could exhibit anti-inflammatory strong bronchodilation potency . V0162 compound potent anticholinergic activity . Secondary PD property V0162 could enhance efficacy antimuscarinic compound could bring new option treatment life-threatening disease .</brief_summary>
	<brief_title>Safety , Preliminary Pharmacokinetics Bronchodilator Properties V0162</brief_title>
	<detailed_description>This study two part . Part A conducted 72 healthy volunteer . Part B conduct 20 patient diagnosed COPD . Part A The primary objective part study assess local tolerability escalate dos V0162 male healthy volunteer . Part B The primary objective part study ass bronchodilator property V0162 maximal tolerate dose ( determined Part A ) COPD patient . In addition , pharmacokinetics vital sign include ECG determine .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion Criteria Part A : Male gender Age 18 50 year include , 18 ≤ Body Mass Index ( BMI ) &lt; 30 kg/m² , Who give write consent participation study , Who , judgement Investigator , likely compliant study , Registered social security insurance system . Inclusion Criteria Part B : Aged 40 65 yearsold , 18 ≤ BMI &lt; 35 kg/m2 , Smokers ≥ 10 pack / year , Moderate severe COPD Registered social security insurance system . Exclusion Criteria Part A : History asthma significant respiratory disorder , History allergic rhinitis , Upper respiratory tract infection last month , Blood eosinophil count ≥ 600/μL , Epilepsy , narrow angle glaucoma , prostatic hypertrophy bladder neck obstruction , Abnormal spirography , Exclusion Criteria Part B : Respiratory tract infection last 6 week , Asthma significant respiratory disorder COPD , Allergic rhinitis , Blood eosinophil count ≥ 600/μL , Epilepsy , narrow angle glaucoma , moderate severe prostatic hypertrophy bladder neckobstruction , Myocardial infarction within previous 6 month , heart failure serious cardiac arrhythmia , Moderate severe renal impairment , Moderate severe hepatic impairment Use shortacting bagonist , Use anticholinergic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>COPD</keyword>
</DOC>